EMA Authorised: Cablivi (Caplacizumab) — Ablynx NV

View source ↗

Summary

The EMA authorised Cablivi (caplacizumab) for thrombotic thrombocytopenic purpura and designated it as an orphan medicine.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Thrombotic Thrombocytopenic Purpura

Drugs mentioned

• CABLIVI (CAPLACIZUMAB)

Snippet

Status: Authorised. Therapeutic area: Purpura, Thrombotic Thrombocytopenic. MAH: Ablynx NV. Decision date: 09/04/2026. Orphan medicine